Abstract
The outcome of liver transplantation has markedly improved in the last 3 decades. Although early post‐transplantation outcomes have improved over time, this is not true of the long‐term outcome. The majority of late deaths are not related to graft dysfunction, and with the advent of new antiviral agents, recurrence of hepatitis B and hepatitis C after transplantation may no longer represent a source of graft loss and patient’s death in the long term. The complications of metabolic syndrome may represent an increasing source of morbidity and mortality after transplantation. This study discusses these modifiable factors associated with late mortality to improve the long‐term results of transplantation.
KEYWORDS
de novo malignancy, immunosuppression, liver transplantation, metabolic syndrome, viral hepatitis
